Floatz Rating
CC46/100
Confidence
Indicative
Sponsor
Sichuan Enray Pharmaceutical Sciences Company
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06048367CT.gov Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Vulva Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cnsi-Fe (this asset) | Sichuan Enray Pharmaceutical Sciences Company | P1 | CC · 46 |
| Indocyanine Green | Istanbul University | P4 | BB |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | Alliance for Clinical Trials in Oncology | P3 | B |
| Technetium-99 | Institut de Cancérologie de Lorraine | P3 | B |
| Durvalumab | M.D. Anderson Cancer Center | P2 | B |
| e7 tcr-t cells | Christian Hinrichs | P2 | B |
| Fondaparinux | Masonic Cancer Center, University of Minnesota | P2 | B |
| Pembrolizumab | UNICANCER | P2 | B |
| Vorinostat | UNICANCER | P2 | CCC |
+26 more in the Vulva Cancer cohort
Other indications for Cnsi-Fe
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Thyroid Cancer | — | P1 | CC · 44 |
| Malignant Pancreatic Neoplasm | — | P1 | CC · 42 |
| Lung Cancer | — | P1 | CC · 40 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Indocyanine GreenIstanbul UniversityBB
- L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-Alliance for Clinical Trials in OncologyB
- Technetium-99Institut de Cancérologie de LorraineB
- DurvalumabM.D. Anderson Cancer CenterB
- e7 tcr-t cellsChristian HinrichsB
Citation
Floatz Terminal. Cnsi-Fe in Vulva Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cnsi-fe-vulva-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →